Heqet Therapeutics

Heqet Therapeutics is a spin-off company from King's College London. It is built on Professor Mauro Giacca's groundbreaking research in cardiac regeneration. The company is currently advancing the preclinical development of its ncRNA-based compounds and is dedicated to developing breakthrough gene therapies to reverse the damage caused by ischemic heart disease.